title: Where now for schizophrenia research?
abstract: Schizophrenia continues to pose a serious challenge to neuroscience and psychiatry as well as to health care systems and to the patients and families who suffer this terrible and disabling illness. Major developments in the past few months in both genetics and drug development oblige us to consider novel drug discovery tactics for future schizophrenia research. Here we review what we consider to be the key issues and some suggested solutions.
authors.affiliation: Division of Brain Sciences, Department of Medicine, Imperial College London, London, United Kingdom. Electronic address: d.nutt@imperial.ac.uk.
authors.forename: David J
authors.initials: DJ
authors.lastname: Nutt
authors.affiliation: Division of Brain Sciences, Department of Medicine, Imperial College London, London, United Kingdom. Electronic address: a.need@imperial.ac.uk.
authors.forename: Anna C
authors.initials: AC
authors.lastname: Need
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D035843:Biomedical Research / Q000639:trends; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D014150:Antipsychotic Agents
keywords: Antipsychotics; Clozapine; Genetics; Glutamate; Schizophrenia; Serendipity